Welcome to our blog page. On this page we want to share our market access expertise build up over the past decades in the BeNeLux.
We wish you a lot of reading pleasure. If you have any questions or comments, you can always contact us.
How to indicate if an innovation is worthwhile to pay for in view of the claimed benefit it will bring? The goal of the NMB is to compare two interventions by subtracting the NMB of ‘intervention A’ from the NMB of ‘intervention B’, resulting in the incremental NMB (iNMB).
Do you understand the potential impact of using 2 independent datasets? In this blog, we provide you a taste of some basic insights.
Always wondered how health economic models work? Good news: this blog is developed to guide you through the basic elements of ‘health state transition models’.
To estimate a launch date, some questions will pop-up. Based on the answers, (in combination with a strong strategy) a realistic estimate of the procedural time will become valid.
All market access colleagues involved in the preparation of economic files will be confronted with the aspect of inflation. There are 2 viewpoints versus ‘today’.
We all know that the pathway between the ‘eureka’ moment and the implementation is long. If needed the regulatory bodies can decide to initiate a ‘fast track procedure’.
‘Success’ is usually the achievement of an expected outcome which is driven by a predefined process.
If you estimate a market share and present this to the sales and marketing department, their input will show high variance. How can you reduce that variance and how can you achieve the best and realistic estimation of the market shares?
HTA bodies should take indirect costs in the scope to assess the cost/benefit of innovation.
A robust budget impact estimation starts with knowledge about the volume of patients. But, how to best estimate the optimal target population?
